ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment. In this study, we demonstrated the role of interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) in MM PI resistance. Gain-...
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
American Society for Clinical investigation
2022-10-01
|
| Edice: | JCI Insight |
| Témata: | |
| On-line přístup: | https://doi.org/10.1172/jci.insight.157081 |